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Aim: We have explored the association of the upper airway symptoms related to cough with
exacerbation frequency, sputum microbiology and inflammatory markers in patients with
non cystic fibrosis bronchiectasis.
Methods: Patients with bronchiectasis completed the Hull Airway Reflux Questionnaire
(HARQ). A score of >13 was taken to indicate the presence of reflux. Patients were
followed-up with longitudinal spirometry, sputum culture and Leicester cough questionnaire
(LCQ). Myeloperoxidase (MPO), free neutrophil elastase (NE) activity, Interleukin (IL)-8 and
Tumour Necrosis Factor (TNF)-a was measured from spontaneous sputum samples.
Results: 163 completed the study. 59.5% were female. Mean age was 65.7 years. 73.6% re-
ported airway reflux using HARQ.
Patients with airway reflux had more severe cough symptoms as assessed by the LCQ [15.2
(3.5) vs. 19.4 (1.9)], p < 0.001. Sputum levels of MPO, NE, IL-8 and TNF-a were all significantly
higher in the reflux positive group (p < 0.05 for all comparisons).
In a multivariable logistic regression, airway reflux was independently associated with cough
severity (3.27, standard error 0.81, p Z 0.0002). Airway reflux, age, FEV1 % predicted and
colonization with Pseudomonas aeruginosa were independently associated with an increased
risk of 3 bronchiectasis exacerbations in one year.
Conclusion: The symptoms of airway reflux independently predict severity and exacerbation
frequency in non cystic fibrosis bronchiectasis.
ª 2013 Elsevier Ltd. All rights reserved.131 242 1921; fax: þ44 01312421870.
ail.com (P. Mandal).
3 Elsevier Ltd. All rights reserved.
13.04.006
Symptoms of airway reflux 1009Introduction
the study (approved by Scotland REC A; approval No. 10/First described by Laennec in 1819, bronchiectasis is a
disease of both children and adults characterized by
inflamed and dilated airways. Bronchiectasis remains a
chronic debilitating condition with most patients suffering
daily symptoms of cough and sputum and a progressive
course punctuated with exacerbations. It has been sug-
gested that recurrent aspiration of gastric contents trig-
gering tracheobronchial inflammation is a potential
aetiological factor in bronchiectasis.1,2 In a study in 1999,
with 100 bronchiectasis patients and 94 controls, it was
concluded that in bronchiectasis, patients who tested
positive for the Helicobacter pylori (HP) and suffered from
acid reflux had lower percent predicted FEV1 and FVC
compared to healthy controls, suggesting that HP may have
a role in the pathogenesis of bronchiectasis.3 A high sero-
prevalence (76%) of HP in patients with bronchiectasis has
been detected4 and it has been proposed that aspiration of
HP exotoxins may contribute to airway inflammation.4
Chronic cough is arbitrarily defined as a cough lasting for
more than 8 weeks. Although conventionally regarded as
being caused by three main aetiologies, gastroesophageal
reflux, asthma and postnasal drip, chronic cough is
increasingly considered a single entity, the Cough Hyper-
sensitivity Syndrome.5 It has been demonstrated that in
patients with chronic cough and peptic gastroesophageal
reflux aspiration of both acid and weakly acidic refluxate is
associated with symptoms.6e8 Similarly other respiratory
disease symptom association studies have shown a corre-
lation between events and episodes of non acid or mildly
acid reflux.9 The extra oesophageal symptoms of reflux into
the airways (chronic cough, hoarseness, globus and chronic
laryngitis) are thought to be due to damage of the respi-
ratory epithelium and appear unrelated to pH of the
refluxate.7 Indeed cough due to reflux frequently presents
without heartburn and has been given the misnomer of si-
lent reflux. Here the term airway reflux is used to describe
this extra oesophageal reflux of diverse composition.10
That classic gastroesophageal reflux disease is a co-
morbidity in patients with bronchiectasis is suggested by
the reported high prevalence compared to the general
population (range of 10e20% in the general population).11
Gastroesophageal reflux is associated with a decreased
health-related quality of life (HRQoL) in individuals without
lung disease who have symptoms of heartburn and acid
regurgitation,12 but the degree of compromise to health-
related quality of life in patients with bronchiectasis has
not been studied.
The aim of our study was to assess the contribution of
symptoms of airways reflux to cough severity and exacer-
bation frequency in patients with non cystic fibrosis
bronchiectasis.
Methods
Study design
Patients were recruited from the South East of Scotland
Bronchiectasis Clinic, over 1 year from March 2010 to March
2011, into a prospective study. Patients gave informedconsent and the Local Research Ethics committee approved
S1103/3).
Patient selection
Patients with clinically significant bronchiectasis confirmed
by high resolution CT (HRCT) scan who were clinically sta-
ble with no exacerbation or antibiotic therapy in the pre-
vious four weeks were eligible for entry in to the study.
Patients taking proton pump inhibitors or H2 receptor an-
tagonists at the time of the study were excluded.
Hull airways reflux questionnaire
Patients were asked to complete the Hull Airways Reflux
Questionnaire (HARQ), a self administered, validated in-
strument, which sensitively and reproducibility assesses the
symptom complex of airway reflux.13 There are 14 ques-
tions each rated between 0 and 5, where 0 equals no
problem and 5 equals frequent/severe problem. A score of
13/70 has been shown to be the upper limit in a normal
population and a score of >13 was taken to indicate the
presence of airways reflux. (See Appendix 1 in online
supplement).
Cough severity
Cough severity was assessed using the Leicester Cough
Questionnaire (LCQ).14 The LCQ has 19 items divided into 3
domains: physical (8 items), psychological (7 items) and
social (4 items). The total severity score ranges from 3 to
21, where a lower score indicates a greater impairment of
health status due to cough. We have previously validated
the Leicester Cough Questionnaire for use in non cystic
fibrosis bronchiectasis.15
Exacerbations
The current BTS guidelines for non cystic fibrosis bronchi-
ectasis define an exacerbation as presentation with an
acute deterioration (usually over several days) with wors-
ening local symptoms (cough, increased sputum volume or
change of viscosity, increased sputum purulence with or
without increasing wheeze, breathlessness, haemoptysis)
and/or systemic upset.16 The frequency of outpatient
antibiotic courses in the 1 year following study entry was
determined by patient interview and confirmed by exami-
nation of hospital prescription and general practitioner
records.
Sputum microbiology
Sputum was collected into a sterile container over a four
hour period from wakening. 1 ml of the sample was pro-
cessed for routine qualitative microbiology. The remaining
sample was ultracentrifuged at 23 200 rpm for 90 min at
4 C. The sol phase was removed and immediately frozen
at 70 C.
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as the isolation on two or more occasions in the preceding
12 months of a potential pathogenic organism.
Lung function
Forced Expired Volume in 1 Second (FEV1), Forced Vital
Capacity (FVC) and FEV1/FVC ratio was recorded, according
to national guidelines.17
Measurement of inflammatory mediators in sputum
sol
All assays were validated for the presence of sputum as
described18 and demonstrated <10% interassay co-efficient
of variation with >80% recovery of spiked recombinant
proteins into sputum samples. Measurement of sputum
Interleukin 8 (IL-8) (Quantikine HS Human CXCL-8, IL-8
Immunoassay, R&D Systems, USA) and sputum Tumour Ne-
crosis Factor-a (TNF-a) (Quantikine HS High Sensitivity,
Human TNF-a Immunoassay, R&D Systems, Minneapolis,
USA), were determined using commercially available
sandwich enzyme-linked immunosorbent assay kits ac-
cording to the instructions of the manufacturers.
Myeloperoxidase (MPO) activity was measured by a
chromogenic substrate assay. This has been shown to
reflect the number of neutrophils in samples of lung se-
cretions. Free neutrophil elastase (NE) activity in sputum
was measured spectrophotometrically using the synthetic
substrate methoxysuccinyl-ala-ala-pro-valparanitroanilide
(MeOSAAPVpNa) (Sigma).19,20
Statistical analysis
All data were analysed using Graphpad prism (Graphpad
software, San Diego, CA, USA). For demographic and clin-
ical variables, data are presented as mean (standard error)
for continuous variables and n (%) for categorical variables
unless otherwise stated. Adjustment for potential con-
founders was achieved using multivariable logistic regres-
sion. Multivariable regression models were constructed by
using cough and exacerbation frequency as the dependant
variable and age, gender, airway reflux, % predicted FEV1
and chronic colonization with Pseudomonas aeruginosa as
independent variables. Model fit was assessed using theTable 1 Baseline characteristics of study population.
Overall
(n Z 163)
Reflux
(n Z
Age 65.7 (0.8) 64.3 (
Gender (% female) 59.5% 59.2%
Inhaled corticosteroids 90 (55.2%) 77 (64
FEV1 (% predicted) 75% 72%
Radiological
severity (3 lobes)
101 (62%) 80 (66
Chronically colonized 101 (62%) 82 (68
Exacerbations
requiring antibiotic
79.8% 88.3%HosmereLemeshow goodness of fit test (P > 0.05 indicates
adequate model fit). Results are presented as adjusted
odds ratio (AOR) with 95% CIs. A p value of <0.05 was
considered statistically significant for each analysis.
Results
The baseline characteristics of the patients in the study
cohort are presented in Table 1. In 58% of patients, cause of
bronchiectasis identified was idiopathic, in 31% post infec-
tive and 11% other causes including autoimmune and
immunological. In the reflux positive group, patients had
more severe bronchiectasis with a lower FEV1 % predicted
(72%) and more lobes affected by bronchiectasis on HRCT
(66.7%). Additionally, in the reflux positive group, more
patients were chronically colonized with microorganisms
(68.3%) and had a greater exacerbation frequency (88.3%)
as compared to the reflux negative group.
Colonization
68% and 44% were chronically colonized in the reflux posi-
tive and negative group respectively. Table 2 summaries
the colonizing organisms isolated. Eighteen patients in the
reflux positive group and 5 in the reflux negative group
isolated more than 1 pathogen. No mycobacterial or fungal
growth was detected in the sputum samples studied. Anti-
biotics were prescribed in accordance with the available
sensitivity results from our microbiology laboratory.
Exacerbations requiring antibiotics
Number of exacerbations needing antibiotic therapy was
recorded for 1 year following study entry. 29% of the pa-
tients in the reflux positive group had more than 5 exac-
erbations in one year compared to 3% in the reflux negative
group. Table 3 summarizes the number required in each
group.
Inflammatory mediators
Sputum levels of TNF-a, IL-8, MPO and NE were all signifi-
cantly higher in the group with airway reflux; p < 0.05 for
all comparisons. (Fig. 1).positive
120; 73.6%)
Reflux negative
(n Z 43; 26.4%)
P value
0.9) 69.8 (1) 0.2
62.8% 0.8
.1%) 13 (30.2%) <0.01
85% 0.04
.7%) 21 (48.8%) <0.01
.3%) 19(44.2%) <0.01
55.9% <0.01
Table 2 Microorganisms isolated from spontaneous sputum samples in each group.
Microorganism Reflux positive
(n Z 120)
Reflux negative
(n Z 43)
Enteric gram negative organisms (P. aeruginosa, E. coli, Klebsiella) 25% 9.3%
Other potential pathogenic organisms
(H. influenzae, M. catarrhalis, S. pneumoniae
and S. aureus e methicillin sensitive)
58.3% 46.5%
Mixed normal flora 31.7% 55.8%
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Patients with airways reflux had more severe cough symp-
toms as assessed by the LCQ, (p < 0.001, as compared to
reflux negative patients). The minimum clinically signifi-
cant difference in LCQ is 1.3 units and in this study, the
difference was between the two groups was 4.2 units [15.2
(3.5) in reflux positive group vs. 19.4 (1.9) in reflux negative
group].
Multivariate logistic regression
Cough severity
After adjusting for age, gender, FEV1 % predicted and
colonization with P. aeruginosa, airway reflux was inde-
pendently associated with cough severity (3.27, standard
error 0.81, p Z 0.0002).
Exacerbations
Reflux, colonisation with P. aeruginosa, lower FEV1 % pre-
dicted and younger age predisposed to 3 bronchiectasis
exacerbations in one year (Table 4).
Discussion
In this prospective study, we investigated the contribution
of symptoms of airways reflux to cough severity and exac-
erbation frequency in patients with non cystic fibrosis
bronchiectasis. We found that symptoms of airway reflux
are common in bronchiectasis. Patients who were reflux
positive as per the HARQ, had more severe bronchiectasis
as indicated by their significantly lower % predicted FEV1,
number of lobes affected by bronchiectasis on HRCT scan,
chronic colonization with potentially pathogenic microor-
ganisms and exacerbations frequency as compared to their
reflux negative counter parts. Inflammatory mediators
(including TNF-a, IL-8, MPO and NE) were all significantly
higher in the reflux positive group. In addition, this group
had worse quality of life due to cough as calculated by the
Leicester Cough Questionnaire.Table 3 Exacerbation frequency.
Reflux positive
(n Z 120)
Reflux negative
(n Z 43)
None 12% 44%
1e2 38% 46%
3e5 21% 7%
>5 29% 3%In a multivariable analysis, after adjusting for age,
gender, FEV1 % predicted and colonization with P. aerugi-
nosa, airway reflux was independently associated with
cough severity and exacerbation frequency.
Gastroesophageal reflux is associated with a decreased
HRQoL in individuals without lung disease who have symp-
toms of heartburn and acid regurgitation,12 but the degree
of compromise to health-related quality of life in patients
with bronchiectasis has not been studied. Our study showed
that those patients who were reflux positive had worse
HRQoL.
Although, the inflammatory cytokines and chemokines
were raised in the sputum of patients with reflux positive
disease, it is perhaps difficult for the authors to
conclude that reflux contributes to disease severity in
bronchiectasis.
In bronchiectasis, there are few markers in stable state
to predict outcome. Interventional studies to date suggest
that sputum volume, colour and bacteriology, exercise ca-
pacity, health-related quality of life indices and exacer-
bation frequency may be relevant predictors of outcome in
bronchiectasis.21
There is a definite need to establish more reliable
markers of prognosis in bronchiectasis to predict disease
outcome in the stable state. The current study prospec-
tively addresses the ability of questionnaire derived symp-
toms of airway reflux in predicting outcome. We have
shown that patients with high symptom scores had worse
cough related quality of life and had more frequent exac-
erbation. We suggest the HARQ questionnaire is a useful
adjunct to other markers mentioned above in the clinical
assessment of patients with a potential to guide both
prognosis and therapy.
The diagnosis of reflux in airway disease is problematic.
The previous concentration on acid related symptoms and
signs is understandable, given their known causative role in
oesophageal disease, but studies using simple pH criteria to
diagnose airway gastroesophageal reflux have found a low
symptom association probability.22 Non or mildly acid extra
oesophageal reflux is now a well established etiological
mechanism in a number of both upper and lower airway
diseases. However the absence of simple objective tests to
quantify the particulate mist causing disease has led to the
use of a variety of questionnaires such as the Reflux
Symptom Index.23 Here we have used the HARQ to char-
acterize the cough associated with airway reflux. This
questionnaire was developed using the symptom complex
and the known associated physiological features of extra
oesophageal gastroesophageal reflux disease. We have used
this assessment tool to provide an evaluation of both acid
and non acid reflux episodes over the preceding month.13
Figure 1 Inflammatory mediators IL-8, TNF-a, MPO and free NE were significantly higher in the reflux positive group; *p < 0.05 for
all comparisons.
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nism in patients with chronic cough or is a mere aggravating
factor that contributes to an abnormally sensitive cough
reflex is open for debate.24
Several studies have studied the association of gastro-
esophageal reflux and respiratory disease. The anatomical
proximity of the human airways and the digestive tract
predisposes to interrelated pathology.25,26 The extra oeso-
phageal manifestations of reflux are generally treated with
the combination of dietary hygiene advice (changes in diet
and behaviour modification) and pharmacological therapy.
Proton pump inhibitors were considered the mainstay of
pharmacological treatment of the entire spectrum of
gastroesophageal reflux and to limit any potential con-
founding effects, we excluded patients who were on proton
pump inhibitor or H2 receptor antagonist at the time of the
study. However they have no effect on the frequency of
reflux episodes, but merely increase the pH of the reflux-
ate. Recent studies in both severe asthma and chronic
cough have shown no effect of acid suppression on either
objective and subjective scores.27,28 Promotility agents
such as dopaminergic agonists and azithromycin29 are moreTable 4 Multivariable logistic regression assessing risk factors f
Variables Adjusted
odds ratio
Airway reflux 7.68
Age 0.92
FEV1 % predicted 0.1
Chronic colonization with P. aeruginosa 5.34rational alternatives in the therapy of non acid airway
reflux.
Limitations
We accept that the study has a couple of limitations.
Sputum pepsin measurement in addition to the HARQ
questionnaire would have been additive because it truly
reflects acid reflux although does not measure gaseous
reflux. Also, this is an observational cohort study and we do
not know for certain whether the association is due to
airways reflux or due to severe bronchiectasis causing
increased cough and hence airways reflux. Hence random-
ized controlled trials in bronchiectasis are needed to
determine if airways reflux intervention is effective.
Conclusion
Symptoms of airways reflux are independently associated
with cough severity and exacerbation frequency in patients
with non cystic fibrosis bronchiectasis. Randomizedor bronchiectasis exacerbation.
95% confidence
interval
P value HosmereLemeshow
goodness of fit test
1.1e53.5 0.03 0.14
0.87e0.99 0.02
0.01e0.74 0.02
1.48e53.5 0.01
Symptoms of airway reflux 1013controlled trials assessing the role of anti-reflux therapy
and promotility agents in treating cough are needed to
explore this association.
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